Literature DB >> 16102999

Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

David Gosal1, Owen A Ross, Joe Wiley, G Brent Irvine, Janet A Johnston, Mathias Toft, Ignacio F Mata, Jennifer Kachergus, Mary Hulihan, Julie P Taylor, Sarah J Lincoln, Matthew J Farrer, Timothy Lynch, J Mark Gibson.   

Abstract

The role of genetics in parkinsonism has been confirmed over the last decade with the identification of genetic variation in seven genes, which are causative in familial forms of the disorder. A number of pathogenic mutations have been identified in the latest gene LRRK2, with a Gly2019Ser amino acid substitution identified in two siblings and one patient with idiopathic Parkinson's disease from Ireland. The clinical features resemble the idiopathic variant with a tremor predominant clinical picture shared by the siblings, slow progression of symptoms, and no observation of cognitive disturbance in all. The family and the sporadic individual were apparently not related and originated from different regions of Ireland, although haplotype analysis does suggest they share a common founder. The influence of the G2019S substitution on protein function and disease phenotype has yet to be fully resolved, but its elucidation will undoubtedly further our understanding of the mechanisms underlying Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16102999     DOI: 10.1016/j.parkreldis.2005.05.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  11 in total

1.  Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.

Authors:  Min Liu; Stephanie Kang; Soumya Ray; Justin Jackson; Alexandra D Zaitsev; Scott A Gerber; Gregory D Cuny; Marcie A Glicksman
Journal:  Biochemistry       Date:  2011-10-07       Impact factor: 3.162

Review 2.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 3.  PARK8 LRRK2 parkinsonism.

Authors:  Kristoffer Haugarvoll; Zbigniew K Wszolek
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

4.  Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis.

Authors:  Chi G Weindel; Eduardo L Martinez; Xiao Zhao; Cory J Mabry; Samantha L Bell; Krystal J Vail; Aja K Coleman; Jordyn J VanPortfliet; Baoyu Zhao; Allison R Wagner; Sikandar Azam; Haley M Scott; Pingwei Li; A Phillip West; Jason Karpac; Kristin L Patrick; Robert O Watson
Journal:  Cell       Date:  2022-07-30       Impact factor: 66.850

Review 5.  The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.

Authors:  Margrethe A Olesen; Francisca Villavicencio-Tejo; Rodrigo A Quintanilla
Journal:  Transl Neurodegener       Date:  2022-07-04       Impact factor: 9.883

6.  Syndromic approach to Parkinson's disease: role of functional imaging.

Authors:  Chong Sik Lee; Sun Ju Chung; Jae Seung Kim
Journal:  J Clin Neurol       Date:  2006-06-20       Impact factor: 3.077

Review 7.  Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

Authors:  Saskia Biskup; Andrew B West
Journal:  Biochim Biophys Acta       Date:  2008-10-10

8.  LRRK2 and mitochondria: Recent advances and current views.

Authors:  Alpana Singh; Lianteng Zhi; Hui Zhang
Journal:  Brain Res       Date:  2018-06-09       Impact factor: 3.252

9.  Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

Authors:  Tanya Simuni; Michael C Brumm; Liz Uribe; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; Roy N Alcalay; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Kelly Nudelman; Duygu Tosun-Turgut; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha Hutten; Susan Bressman; Kenneth Marek
Journal:  Mov Disord       Date:  2020-02-19       Impact factor: 10.338

10.  LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease.

Authors:  Ahmed Bouhouche; Houyam Tibar; Rafiqua Ben El Haj; Khalil El Bayad; Rachid Razine; Sanaa Tazrout; Asmae Skalli; Naima Bouslam; Loubna Elouardi; Ali Benomar; Mohammed Yahyaoui; Wafa Regragui
Journal:  Parkinsons Dis       Date:  2017-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.